公开(公告)号：US20220135638A1

公开(公告)日：2022-05-05

申请号：US17279266

申请日：2019-09-24

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Hiroshi IMOTO ,  Mari ADACHI ,  Yoko KANEMATSU ,  Taiji ASAMI ,  Ayumu NIIDA ,  Naoki NISHIZAWA ,  Derek Cecil COLE ,  Mack FLINSPACH ,  Nick SCORAH ,  Abhijit Suresh BHAT

IPC: C07K14/575 ,  A61K9/00 ,  A61K9/08 ,  A61K47/02 ,  A61K9/20 ,  A61P1/08

Abstract: The present disclosure provides GIP receptor agonist peptide compounds having an activating action on GIP receptors and use of the GIP receptor agonist peptide as a medicament for the treatment and/or prevention of diabetes, obesity, emesis, or a symptom or condition associated with diabetes, obesity, or emesis. Specifically, a GIP receptor agonist peptide containing a sequence represented by the formula (I) or a salt thereof, and a medicament comprising the same are provided. Formula I: P1-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A341-A32-A33-A34-A35-A36-A37-A38-A39-A40-A41-P2 (SEQ ID NO: 4), or a salt thereof, wherein each symbol is as defined herein, with the proviso that the GIP receptor agonist peptide does not have an amino acid sequence as provided in SEQ ID NOs: 4-569 disclosed in PCT/JP2018/013540.

公开(公告)号：US20240390508A1

公开(公告)日：2024-11-28

申请号：US18685457

申请日：2022-08-19

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takatoshi YOGO ,  Hideyuki SUGIYAMA ,  Kenichi MIYATA ,  Hiroyuki TAKADA ,  Masato YOSHIDA ,  Ryosuke TOKUNOH ,  Yasuo NAKAGAWA ,  Masato NIWA ,  Shigekazu SASAKI ,  Masaki OHUCHI ,  Naoki SAWAI ,  Masatoshi TAKUWA ,  Yujiro UCHINO ,  Yoko KANEMATSU ,  Koichiro FUKUDA ,  Takanori YOKOTO ,  Tetsuya NAGATA ,  Hiroki YAMADA

IPC: A61K47/64 ,  A61K38/17 ,  A61K48/00 ,  C12N15/113

Abstract: The present invention aims to provide a novel drug delivery system (DDS) technique capable of selectively delivering a drug (compound containing oligonucleotides for producing at least partially functional dystrophin protein) to muscle tissues such as cardiac muscle, skeletal muscle and the like and efficiently introducing the drug into the muscle cells. The present invention relates to a conjugate or a salt thereof including the following: (1) a peptide that binds to a transferrin receptor, and contains the amino acid sequence shown in SEQ ID NO: 1 (Ala-Val-Phe-Val-Trp-Asn-Tyr-Tyr-Ile-Ile-Ser-Cys); or an amino acid sequence resulting from substitution, deletion, addition, and/or insertion of not less than one and not more than 10 amino acid residues in the amino acid sequence shown in SEQ ID NO: 1, and (2) a compound comprising an oligonucleotide for producing an at least partially functional dystrophin protein.